Drug Profile
Ornithine phenylacetate - Ocera Therapeutics
Alternative Names: L-Ornithine phenylacetate; MNK 6106; MNK-6105; OCR-002; OP; Ornithine hydrochloride/sodium phenylacetate; Sodium phenylacetate/ornithine hydrochloride; UCL-L1VLatest Information Update: 30 Sep 2021
Price :
$50
*
At a glance
- Originator University College London
- Developer Ocera Therapeutics
- Class Basic amino acids; Diamino amino acids; Esters; Hepatoprotectants; Neuroprotectants; Phenylacetates; Small molecules
- Mechanism of Action Aminohydrolase modulators; Ammonia scavengers; NF-kappa B modulators; Nitric oxide synthase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Hepatic encephalopathy
- Phase II Liver cirrhosis; Liver failure
- No development reported Non-alcoholic fatty liver disease
Most Recent Events
- 22 Sep 2021 Mallinckrodt withdraws a phase III trial, prior to enrolment, for Hepatic-encephalopathy (IV, Infusion) (NCT04128462)
- 28 May 2021 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in USA (IV, Infusion)
- 28 May 2021 Mallinckrodt plans a phase III trial for Hepatic-encephalopathy (IV) in first half of 2022 in USA